Overview: Modified Acid-Fast Leprosy Panel
Introduction: The Modified Acid-Fast Leprosy Panel is a diagnostic tool designed to detect leprosy bacilli using FFPE tissue. In India, leprosy remains endemic (~1.2 lakh new cases/year, highest globally), with multibacillary forms showing acid-fast bacilli (AFB) on modified Ziehl-Neelsen stain. High morbidity from under-testing in rural/low-SES patients with hypopigmented patches or nerve thickening, limited histopathology labs, delayed MDT leading to deformities, disability, or stigma. Per dermatology practices aligned with NLEP and ICMR guidelines, the test employs microscopy for modified acid-fast stain and tissue morphology over 1-2 days with high specificity, valuable for confirming Mycobacterium leprae in skin/nerve biopsies. This diagnostic falls under infection screening and targets patients with suspected leprosy (anesthetic patches, thickened nerves), addressing accurate detection to guide MDT (rifampicin, dapsone, clofazimine) and disability prevention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise bacillary confirmation and reducing leprosy burden. Its FFPE-based approach ensures reliable AFB visualization.
Other Names: Leprosy Stain Pnl.
FDA Status: FDA approved, CLIA certified for histopathology, compliant with 2025 standards.
Historical Milestone: Modified AFB stain standard for leprosy; in India, key in NLEP diagnosis.
Purpose: The test assesses 2 parameters including modified acid-fast stain to guide leprosy bacilli detection, confirm infection, inform MDT.
Test Parameters: 1. Modified Acid Fast Stain, 2. Tissue Morphology.
Pretest Condition: No fasting required; patients should have skin biopsy.
Specimen: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; staining possible long-term.
Medical History: Patients should provide details on skin lesions, nerve thickening.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed leprosy including disability, benefits of staining, and no additional discomfort (uses existing block).
Procedural Considerations: The test involves slide preparation and modified AFB microscopy by trained personnel to ensure accurate bacilli detection and report within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Poor fixation, inadequate sampling, or low bacillary load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive AFB in nerves/skin confirms leprosy, necessitating specialist input.
Specialist Consultation: Dermatologists or leprologists should be consulted for management.
Additional Supporting Tests: Slit-skin smear, PCR for confirmation.
Test Limitations: Bacilli load-dependent; comprehensive approach required.
References: Indian Journal of Leprosy 2024, NLEP Studies India 2023.
